NOTION试验10年结果:TAVI与外科主动脉瓣置换的长期比较
NOTION试验将280例低外科风险的重度主动脉瓣狭窄患者随机分配至自膨胀CoreValve经导管主动脉瓣植入(TAVI)组或外科主动脉瓣置换(SAVR)组。10年随访时,TAVI与SAVR在全因死亡、卒中或心肌梗死的复合终点风险上无差异(均为65.5%),TAVI组严重结构性瓣膜 deterioration(SVD)风险更低(1.5% vs 10.0%),但生物瓣膜失败(BVF)风险相似。
要点
- 低外科风险重度AS患者10年复合终点风险TAVI与SAVR均为65.5%,无显著差异。
- TAVI组严重SVD发生率显著低于SAVR(1.5% vs 10.0%,HR 0.2)。
- 两组BVF发生率相似(9.7% vs 13.8%),无临床瓣膜血栓。
核心结论
- 在低外科风险重度AS患者中,TAVI与SAVR术后10年主要临床结局风险无差异。
- TAVI组严重生物瓣膜SVD风险低于SAVR,但BVF风险相似。
研究设计与样本
- NOTION试验随机纳入280例患者,TAVI组145例(自膨胀CoreValve瓣膜),SAVR组135例(生物瓣膜)。
- 主要复合终点为全因死亡、卒中或心肌梗死;BVD按VARC-3标准分类。
主要发现
- 无临床瓣膜血栓事件;BVF发生率TAVI 9.7% vs SAVR 13.8%(HR 0.7,95%CI 0.4-1.5,P=0.4)。
关键数值与推荐
- 严重SVD定义:跨瓣压差≥30 mmHg且较基线增加≥20 mmHg,或新发严重瓣内反流。
- BVF定义:瓣膜相关死亡或BVD诊断后不明原因死亡、主动脉瓣再干预或严重SVD的复合终点。
临床怎么用
- 对于低外科风险重度AS患者,TAVI可作为SAVR的替代选择,10年临床结局相当。
- TAVI可能降低严重SVD风险,但需关注NSVD发生率仍较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Transcatheter aortic valve implantation (TAVI) has become a viable treatment option for patients with severe aortic valve stenosis across a broad range of surgical risk. The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize patients at lower surgical risk to TAVI or surgical aortic valve replacement (SAVR). The aim of the present study was to report clinical and bioprosthesis outcomes after 10 years. METHODS: The NOTION trial randomized 280 patients to TAVI with the self-expanding CoreValve (Medtronic Inc.) bioprosthesis (n = 145) or SAVR with a bioprosthesis (n = 135). The primary composite outcome was the risk of all-cause mortality, stroke, or myocardial infarction. Bioprosthetic valve dysfunction (BVD) was classified as structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), clinical valve thrombosis, or endocarditis according to Valve Academic Research Consortium-3 criteria. Severe SVD was defined as (i) a transprosthetic gradient of 30 mmHg or more and an increase in transprosthetic gradient of 20 mmHg or more or (ii) severe new intraprosthetic regurgitation. Bioprosthetic valve failure (BVF) was defined as the composite rate of death from a valve-related cause or an unexplained death following the diagnosis of BVD, aortic valve re-intervention, or severe SVD. RESULTS: Baseline characteristics were similar between TAVI and SAVR: age 79.2 ± 4.9 years and 79.0 ± 4.7 years (P = .7), male 52.6% and 53.8% (P = .8), and Society of Thoracic Surgeons score < 4% of 83.4% and 80.0% (P = .5), respectively. After 10 years, the risk of the composite outcome all-cause mortality, stroke, or myocardial infarction was 65.5% after TAVI and 65.5% after SAVR [hazard ratio (HR) 1.0; 95% confidence interval (CI) 0.7-1.3; P = .9], with no difference for each individual outcome. Severe SVD had occurred in 1.5% and 10.0% (HR 0.2; 95% CI 0.04-0.7; P = .02) after TAVI and SAVR, respectively. The cumulative incidence for severe NSVD was 20.5% and 43.0% (P < .001) and for endocarditis 7.2% and 7.4% (P = 1.0) after TAVI and SAVR, respectively. No patients had clinical valve thrombosis. Bioprosthetic valve failure occurred in 9.7% of TAVI and 13.8% of SAVR patients (HR 0.7; 95% CI 0.4-1.5; P = .4). CONCLUSIONS: In patients with severe AS and lower surgical risk randomized to TAVI or SAVR, the risk of major clinical outcomes was not different 10 years after treatment. The risk of severe bioprosthesis SVD was lower after TAVR compared with SAVR, while the risk of BVF was similar.
引用
- Thyregod HGH, Jørgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J. 2024. PMID: 38321820. doi:10.1093/eurheartj/ehae043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。